chromosome 19 open reading frame 18Genealiases: []
Q-omics provides the consensus-scored C19orf18 profile across patient tissues and cancer cell-line models. C19orf18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, C19orf18 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, C19orf18 RNA expression shows 17,316 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, KICH, and UVM as cancer lineages where C19orf18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf18 survival associations across molecular data types. C19orf18 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf18 RNA expression–survival associations across cancer types. High C19orf18 expression shows unfavorable associations in SKCM and LGG, but favorable associations in CESC, BLCA, PAAD and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for C19orf18 RNA expression.
This table summarizes C19orf18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C19orf18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf18 shows lower tumor expression in KICH, HNSC and KIRP and higher tumor expression in STAD, CHOL and PRAD. The KICH box plot shows higher C19orf18 RNA expression in normal versus tumor tissue (log2 FC = −0.526, t-test p < 0.001).
This table shows molecular features associated with C19orf18 in patient tissues and cancer cell lines. In patient samples, C19orf18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
